Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury.

Wermeling DP, Clinch T, Rudy AC, Dreitlein D, Suner S, Lacouture PG.

J Pain. 2010 Jan;11(1):24-31. doi: 10.1016/j.jpain.2009.05.002. Epub 2009 Jul 9.

PMID:
19592310
2.

A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.

Wermeling DP, Record KA, Archer SM, Rudy AC.

Epilepsy Res. 2009 Feb;83(2-3):124-32. doi: 10.1016/j.eplepsyres.2008.10.005. Epub 2008 Nov 29.

PMID:
19046855
3.

Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study.

Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP.

Pharmacotherapy. 2008 Jul;28(7):875-82. doi: 10.1592/phco.28.7.875.

PMID:
18576902
4.

Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ.

Clin Drug Investig. 2004;24(11):633-9.

PMID:
17523726
5.

Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.

Wermeling DP, Record KA, Kelly TH, Archer SM, Clinch T, Rudy AC.

Anesth Analg. 2006 Aug;103(2):344-9, table of contents.

PMID:
16861415
6.

Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.

Wermeling DP, Miller JL, Archer SM, Rayens MK, Rudy AC.

J Clin Pharmacol. 2005 Aug;45(8):969-73. No abstract available.

PMID:
16027409
8.

A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.

Rudy AC, Coda BA, Archer SM, Wermeling DP.

Anesth Analg. 2004 Nov;99(5):1379-86; table of contents.

PMID:
15502034
9.

Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.

Davis GA, Rudy AC, Archer SM, Wermeling DP.

Am J Health Syst Pharm. 2004 Feb 1;61(3):261-6.

PMID:
14986556
10.

Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis.

Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ.

Pharmacotherapy. 2004 Jan;24(1):26-32.

PMID:
14740785
11.

Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.

Coda BA, Rudy AC, Archer SM, Wermeling DP.

Anesth Analg. 2003 Jul;97(1):117-23, table of contents.

PMID:
12818953
12.

Hydromorphone transfer into breast milk after intranasal administration.

Edwards JE, Rudy AC, Wermeling DP, Desai N, McNamara PJ.

Pharmacotherapy. 2003 Feb;23(2):153-8.

PMID:
12587803
13.

Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.

Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC.

J Clin Pharmacol. 2001 Nov;41(11):1225-31.

PMID:
11697755
14.

Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers.

Rudy AC, Liu Y, Brater C, Hall SD.

J Clin Pharmacol. 1998 Feb;38(2S):3S-10S.

PMID:
9549653
15.

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.

Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA.

Vaccine. 1997 Aug-Sep;15(12-13):1314-8.

PMID:
9302736
16.

The Influence of Misoprostol on the Adverse Renal Effects and Stereospecific Pharmacokinetics of Ibuprofen in Chronic Renal Insufficiency.

Rudy DW, Rudy AC, Black PK, Liu Y, Hamman M, Brater DC.

Am J Ther. 1995 Nov;2(11):864-874.

PMID:
11854800
17.

Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.

Rudy AC, Knight PM, Brater DC, Hall SD.

J Pharmacol Exp Ther. 1995 Apr;273(1):88-93.

PMID:
7714818
18.

The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Rudy AC, Figueroa NL, Hall SD, Brater DC.

Br J Clin Pharmacol. 1994 Jan;37(1):1-5.

19.

Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans.

Hall SD, Rudy AC, Knight PM, Brater DC.

Clin Pharmacol Ther. 1993 Apr;53(4):393-400.

PMID:
8477555
20.

Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients.

Rudy AC, Bradley JD, Ryan SI, Kalasinski LA, Xiaotao Q, Hall SD.

Ther Drug Monit. 1992 Dec;14(6):464-70.

PMID:
1485367
21.

Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis.

Bradley JD, Rudy AC, Katz BP, Ryan SI, Kalasinski LA, Brater DC, Hall SD, Brandt KD.

J Rheumatol. 1992 Jan;19(1):130-4.

PMID:
1556674
22.

Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen.

Rudy AC, Knight PM, Brater DC, Hall SD.

J Pharmacol Exp Ther. 1991 Dec;259(3):1133-9. Erratum in: J Pharmacol Exp Ther 1992 Mar;260(3):1456.

PMID:
1762067
23.

Binding of pyrimethamine to human plasma proteins and erythrocytes.

Rudy AC, Poynor WJ.

Pharm Res. 1990 Oct;7(10):1055-60.

PMID:
2281036
24.

High-performance liquid chromatographic determination of the stereoisomeric metabolites of ibuprofen.

Rudy AC, Anliker KS, Hall SD.

J Chromatogr. 1990 Jun 29;528(2):395-405.

PMID:
2384577

Supplemental Content

Support Center